I lead the Computational Biology team at Kymera Therapeutics, which is developing new therapies in immunology and oncology using an exciting new platform based on targeted protein degradation (TPD). TPD hijacks the ubiquitin-proteasome system of the cell and uses it to degrade therapeutic targets.
Till May 2017, I was a postdoc in the Meissner Lab in the Department of Stem Cell and Regenerative Biology (SCRB) at Harvard and affiliated with the Broad Institute. My research utilized genomic and epigenomic profiling to understand mechanisms of gene regulation that determine cellular identity, and I specialized in developing computational methods for the integrated analysis of large genome-wide datasets.
